This Event is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Event: 933
Key Event Title
KE6 : Depletion, Nitric Oxide
Short name
Biological Context
Level of Biological Organization |
---|
Cellular |
Cell term
Organ term
Organ term |
---|
blood |
Key Event Components
Process | Object | Action |
---|---|---|
nitric oxide biosynthetic process | nitric oxide | decreased |
Key Event Overview
AOPs Including This Key Event
AOP Name | Role of event in AOP | Point of Contact | Author Status | OECD Status |
---|---|---|---|---|
Hypertension | KeyEvent | Brendan Ferreri-Hanberry (send email) | Not under active development | Under Development |
Taxonomic Applicability
Life Stages
Life stage | Evidence |
---|---|
All life stages | High |
Sex Applicability
Term | Evidence |
---|---|
Unspecific | High |
Key Event Description
Nitric oxide (NO), constitutively produced by endothelial nitric oxide synthase (eNOS), is an important regulator of vascular homeostasis. Endothelial-derived NO promotes vasodilation and protects against atherogenesis through the inhibition of vascular smooth muscle cell proliferation and migration, platelet aggregation and adhesion, and leukocyte adherence. Its effects have an influence on vascular resistance, blood pressure, vascular remodeling and angiogenesis (Luo et al., 2000). Dysfunctional eNOS as a result of eNOS uncoupling leads to a decrease or loss of NO bioavailability and an elevation of superoxide production (Crabtree et al., 2009). The imbalance of NO and superoxide is associated with many disorders, such as hypertension, atherosclerosis, hypercholesterolemia, and diabetes mellitus.
How It Is Measured or Detected
NO production can be measured through the conversion of L-arginine to L-citrulline (de Bono et al., 2007) , in situ fluorescent signal detection with fluorescent indicator DAF-2 DA (Itoh et al., 2000; Nagata et al., 1999; Qiu et al., 2001), EPR spin-trapping (Xia et al., 2000), and the determination of total nitrate and nitrite concentration (Crabtree et al., 2009; Du et al., 2013).
Domain of Applicability
NO depletion was observed in humans, cows, mice and rats (Chen et al., 2010; Crabtree et al., 2009; De Pascali et al., 2014; Du et al., 2013; Jayaram et al., 2015).
References
de Bono, J.P., Warrick, N., Bendall, J.K., Channon, K.M., and Alp, N.J. (2007). Radiochemical HPLC detection of arginine metabolism: Measurement of nitric oxide synthesis and arginase activity in vascular tissue. Nitric Oxide 16, 1–9.
Chen, X., Xu, J., Feng, Z., Fan, M., Han, J., and Yang, Z. (2010). Simvastatin combined with nifedipine enhances endothelial cell protection by inhibiting ROS generation and activating Akt phosphorylation. Acta Pharmacol. Sin. 31, 813–820.
Crabtree, M.J., Tatham, A.L., Al-Wakeel, Y., Warrick, N., Hale, A.B., Cai, S., Channon, K.M., and Alp, N.J. (2009). Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J. Biol. Chem. 284, 1136–1144.
De Pascali, F., Hemann, C., Samons, K., Chen, C.-A., and Zweier, J.L. (2014). Hypoxia and reoxygenation induce endothelial nitric oxide synthase uncoupling in endothelial cells through tetrahydrobiopterin depletion and S-glutathionylation. Biochemistry (Mosc.) 53, 3679–3688.
Du, Y., Navab, M., Shen, M., Hill, J., Pakbin, P., Sioutas, C., Hsiai, T.K., and Li, R. (2013). Ambient ultrafine particles reduce endothelial nitric oxide production via S-glutathionylation of eNOS. Biochem. Biophys. Res. Commun. 436, 462–466.
Dumitrescu, C., Biondi, R., Xia, Y., Cardounel, A.J., Druhan, L.J., Ambrosio, G., and Zweier, J.L. (2007). Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc. Natl. Acad. Sci. U. S. A. 104, 15081–15086.
Itoh, Y., Ma, F.H., Hoshi, H., Oka, M., Noda, K., Ukai, Y., Kojima, H., Nagano, T., and Toda, N. (2000). Determination and bioimaging method for nitric oxide in biological specimens by diaminofluorescein fluorometry. Anal. Biochem. 287, 203–209.
Jayaram, R., Goodfellow, N., Zhang, M.H., Reilly, S., Crabtree, M., De Silva, R., Sayeed, R., and Casadei, B. (2015). Molecular mechanisms of myocardial nitroso-redox imbalance during on-pump cardiac surgery. Lancet Lond. Engl. 385 Suppl 1, S49.
Luo, Z., Fujio, Y., Kureishi, Y., Rudic, R.D., Daumerie, G., Fulton, D., Sessa, W.C., and Walsh, K. (2000). Acute modulation of endothelial Akt/PKB activity alters nitric oxide–dependent vasomotor activity in vivo. J. Clin. Invest. 106, 493–499.
Nagata, N., Momose, K., and Ishida, Y. (1999). Inhibitory effects of catecholamines and anti-oxidants on the fluorescence reaction of 4,5-diaminofluorescein, DAF-2, a novel indicator of nitric oxide. J. Biochem. (Tokyo) 125, 658–661.
Qiu, W., Kass, D.A., Hu, Q., and Ziegelstein, R.C. (2001). Determinants of shear stress-stimulated endothelial nitric oxide production assessed in real-time by 4,5-diaminofluorescein fluorescence. Biochem. Biophys. Res. Commun. 286, 328–335.
Xia, Y., Cardounel, A.J., Vanin, A.F., and Zweier, J.L. (2000). Electron paramagnetic resonance spectroscopy with N-methyl-D-glucamine dithiocarbamate iron complexes distinguishes nitric oxide and nitroxyl anion in a redox-dependent manner: applications in identifying nitrogen monoxide products from nitric oxide synthase. Free Radic. Biol. Med. 29, 793–797.